elcuidadodelasalude.org



Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

March 26, 2016

The collaborators plan to compare the genetic and clinical data from EMR derived "cases" to healthy control groups, with the goal of identifying genetic mutations that are associated with the specific SAE. To date, the iSAEC has already made significant genetic discoveries in support of its mission to better understand the role of genetics in drug-induced SAEs. The HMORN-iSAEC collaboration will facilitate the discovery and validation of these and additional genetic findings.

"Many adverse drug reactions are probably a result of genetic differences among patients," said Robert Davis, MD, director of the Kaiser Permanente Center for Health Research-Southeast and a member of the HMO Research Network. "Through our research with the iSAEC, we hope to identify these differences and screen patients before they are treated, thereby reducing morbidity and mortality associated with drug therapies. Because of our large population, ethnic diversity, and the wide range of medications prescribed, the HMORN is an ideal partner for this collaboration."

Source: Edelman Public Relations